Communiqué de presse
Janssen Presents New Data for Talquetamab, a GPRC5DxCD3 Bispecific Antibody, Showing Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
Results from the pivotal MonumenTAL-1 study, including first results from the Phase 2 portion, featured at the 2022 ASH Annual […]